GO:0004507 steroid 11-beta-monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004507 describes steroid 11-beta-monooxygenase activity, a mitochondrial cytochrome P450 activity that catalyzes 11-beta-hydroxylation of steroids using reduced adrenal ferredoxin and O2.
• The activity is carried by CYP11B1 and CYP11B2, two closely related isozymes that differ in their substrate preferences and product profiles.
• CYP11B1 is required for cortisol biosynthesis, whereas CYP11B2 is required for aldosterone biosynthesis; both are expressed in the adrenal cortex.
• Loss- or gain-of-function changes in these isozymes cause disorders such as 11-beta-hydroxylase deficiency, glucocorticoid-remediable aldosteronism, and familial hyperaldosteronism.
• The activity has been detected and measured in recombinant yeast mitochondria and in bovine ovary, showing that it can be studied outside the adrenal gland.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of CYP11B1/CYP11B2 variants and their role in steroidogenesis.
Description
Steroid 11-beta-monooxygenase activity (GO:0004507) is a molecular function that introduces a hydroxyl group at the 11-beta position of steroid substrates. The reaction consumes a steroid, reduced adrenal ferredoxin, and molecular oxygen, and produces an 11-beta-hydroxysteroid, oxidized adrenal ferredoxin, and water. This activity is central to the biosynthesis of glucocorticoids and mineralocorticoids in the adrenal cortex, and it is carried out by the mitochondrial cytochrome P450 enzymes CYP11B1 and CYP11B2. Because the two isozymes are highly similar yet produce different hormonal outputs, they provide a classic system for studying how small sequence differences can redirect steroidogenic flux. Researchers study GO:0004507 to understand adrenal steroidogenesis, to interpret genetic variants that cause hypertension or cortisol excess, and to build cell and animal models that test causality of candidate variants.
steroid 11-beta-monooxygenase activity At A Glance
| GO ID | GO:0004507 |
|---|---|
| GO term | steroid 11-beta-monooxygenase activity |
| Ontology | molecular_function |
| Synonym | steroid 11-beta-hydroxylase activity; steroid 11beta-hydroxylase activity; cytochrome P450 CYP11B1; cytochrome P450 CYP11B2; steroid 11-beta/18-hydroxylase activity |
| Major function | Catalyzes 11-beta-hydroxylation of steroids using reduced adrenal ferredoxin and O2 |
| Representative enzymes | CYP11B1 and CYP11B2 |
| Subcellular context | Mitochondrial cytochrome P450 system in steroidogenic tissues |
| Physiological products | Cortisol and aldosterone pathways |
| Disease relevance | 11-beta-hydroxylase deficiency, glucocorticoid-remediable aldosteronism, familial hyperaldosteronism |
What Is GO:0004507?
In this article, steroid 11-beta-monooxygenase activity means the catalytic activity defined by GO:0004507: a steroid plus reduced adrenal ferredoxin plus O2 are converted to an 11-beta-hydroxysteroid plus oxidized adrenal ferredoxin plus H2O. The activity is a monooxygenase reaction because one atom of molecular oxygen is incorporated into the steroid product while the other is reduced to water, with electrons supplied by reduced adrenal ferredoxin.
Why Is steroid 11-beta-monooxygenase activity Important in Cell Biology?
GO:0004507 is important because it sits at the branch point between glucocorticoid and mineralocorticoid biosynthesis. CYP11B1 activity is needed for cortisol production, while CYP11B2 activity is needed for aldosterone production, and the balance between these products controls blood pressure, salt homeostasis, and the stress response. Genetic or regulatory changes that alter this activity can therefore produce endocrine disease, including hypertension and disorders of sexual development. The activity is also a practical target for experimental work because it can be reconstituted in recombinant systems and measured biochemically, making it tractable for mechanistic and pharmacological studies.
• Defines the terminal step in cortisol biosynthesis, linking the activity to glucocorticoid physiology.
• Defines the terminal step in aldosterone biosynthesis, linking the activity to mineralocorticoid physiology and blood pressure control.
• Explains the biochemical basis of 11-beta-hydroxylase deficiency, a form of congenital adrenal hyperplasia.
• Explains the biochemical basis of glucocorticoid-remediable aldosteronism, in which ectopic expression of the activity causes aldosterone excess.
• Provides a model for understanding how two closely related isozymes can have different substrate and product specificities.
• Supports biochemical assays in recombinant systems such as yeast mitochondria.
• Has been detected in extra-adrenal tissues such as the bovine ovary, suggesting broader roles in steroidogenic tissues.
• Provides a target for genetic testing and experimental modeling of familial hyperaldosteronism.
• Enables structure-function studies of mitochondrial P450 enzymes and their electron transfer partners.
• Supports drug discovery efforts aimed at modulating adrenal steroidogenesis.
What Happens During steroid 11-beta-monooxygenase activity?
Substrate binding and electron transfer
In simple terms: The enzyme first grabs a steroid molecule and receives electrons from a partner protein.
The reaction begins when a steroid substrate binds the CYP11B1 or CYP11B2 active site. Electrons are delivered from reduced adrenal ferredoxin, which is itself reduced by a ferredoxin reductase in the mitochondrial system. This electron transfer prepares the heme iron for oxygen activation.
Oxygen activation and hydroxylation
In simple terms: Oxygen is split, and one oxygen atom is added to the steroid.
Molecular oxygen binds the heme iron, and the reaction uses one oxygen atom to hydroxylate the steroid at the 11-beta position while the other oxygen atom is reduced to water. The product is an 11-beta-hydroxysteroid, and the oxidized adrenal ferredoxin is released to be re-reduced.
Isozyme-specific product formation
In simple terms: Different enzymes make different final hormones from the same starting material.
CYP11B1 primarily catalyzes 11-beta-hydroxylation to produce cortisol precursors, whereas CYP11B2 can also perform 18-hydroxylation and 18-oxidation steps needed for aldosterone synthesis. This functional difference is a key reason the two isozymes are studied separately.
Detection in recombinant and tissue systems
In simple terms: Scientists can measure this activity outside the body.
Recombinant yeast mitochondria expressing 11-beta-hydroxylase can convert 11-deoxycortisol to hydrocortisone, providing a direct biochemical readout of the activity. The activity has also been detected in the bovine ovary, indicating that it can be studied in non-adrenal steroidogenic contexts.
Key Genes Involved in GO:0004507 steroid 11-beta-monooxygenase activity
The genes and proteins most directly associated with GO:0004507 are the cytochrome P450 isozymes CYP11B1 and CYP11B2, together with their electron transfer partners and the transcription factors that control their expression.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP11B1 | Catalyzes 11-beta-hydroxylation for cortisol biosynthesis | Central enzyme for GO:0004507; mutations cause 11-beta-hydroxylase deficiency |
| CYP11B2 | Catalyzes 11-beta- and 18-hydroxylation for aldosterone biosynthesis | Key enzyme for mineralocorticoid synthesis; dysregulation causes hyperaldosteronism |
| FDX1 | Adrenal ferredoxin; supplies electrons to mitochondrial P450s | Required for reconstitution of the activity in vitro |
| FDXR | Ferredoxin reductase; reduces adrenal ferredoxin | Supports electron transfer to CYP11B1/CYP11B2 |
| NR5A1 | Transcription factor regulating steroidogenic genes | Controls expression of adrenal steroidogenic enzymes |
| CREB1 | Transcription factor downstream of ACTH signaling | Regulates cortisol pathway gene expression |
| ATF2 | Stress-responsive transcription factor | May influence adrenal steroidogenic gene expression |
| CYP11A1 | Cholesterol side-chain cleavage enzyme | Upstream of 11-beta-hydroxylation in steroidogenesis |
| HSD3B2 | 3-beta-hydroxysteroid dehydrogenase | Upstream enzyme in cortisol and aldosterone pathways |
| CYP17A1 | 17-alpha-hydroxylase/17,20-lyase | Determines flux toward cortisol versus other steroids |
| CYP21A2 | 21-hydroxylase | Upstream enzyme whose deficiency alters substrate availability |
| STAR | Cholesterol transport protein | Supplies cholesterol for steroidogenesis |
| MC2R | ACTH receptor | Controls adrenal steroidogenic drive |
| POMC | Precursor of ACTH | Regulates adrenal cortisol synthesis |
| HSD11B1 | 11-beta-hydroxysteroid dehydrogenase type 1 | Modulates local glucocorticoid availability |
| HSD11B2 | 11-beta-hydroxysteroid dehydrogenase type 2 | Modulates mineralocorticoid receptor activation |
| KCNJ5 | Potassium channel | Somatic mutations linked to aldosterone-producing adenomas |
| ATP1A1 | Sodium/potassium ATPase | Somatic mutations linked to aldosterone-producing adenomas |
How Is steroid 11-beta-monooxygenase activity Regulated?
The activity is regulated at multiple levels. Transcription of CYP11B1 and CYP11B2 is controlled by adrenal transcription factors and hormonal signals such as ACTH, which adjusts steroidogenic capacity according to physiological demand. In glucocorticoid-remediable aldosteronism, a recombination event places CYP11B1 under the control of the CYP11B2 regulatory region, causing ectopic expression of 11-beta-hydroxylase activity in the aldosterone-producing zone and leading to aldosterone excess. Post-translational regulation of electron transfer partners can also influence flux through the activity.
steroid 11-beta-monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP11B1 | 11-beta-hydroxylase deficiency; congenital adrenal hyperplasia | Knockout or point-mutation cell model with cortisol precursor measurement |
| CYP11B1/CYP11B2 | Glucocorticoid-remediable aldosteronism | Knock-in of chimeric regulatory construct to mimic ectopic expression |
| CYP11B2 | Familial hyperaldosteronism; primary hyperaldosteronism | Overexpression model with aldosterone production readout |
| KCNJ5 | Aldosterone-producing adenoma | Point-mutation knock-in in adrenal cell lines |
| ATP1A1 | Aldosterone-producing adenoma | Point-mutation knock-in with steroid profiling |
11-beta-hydroxylase deficiency and congenital adrenal hyperplasia
Loss of CYP11B1 function reduces cortisol synthesis and shunts precursors toward androgen production, causing a form of congenital adrenal hyperplasia with hypertension and virilization. The biochemical diagnosis and management of this disorder depend on understanding the residual activity of the enzyme.
Glucocorticoid-remediable aldosteronism
In glucocorticoid-remediable aldosteronism, ectopic expression of CYP11B1 in the aldosterone-producing zone causes aldosterone excess that is suppressible by glucocorticoids. This disorder illustrates how regulatory changes, rather than coding mutations, can alter the activity and produce hypertension.
Familial hyperaldosteronism
Familial forms of hyperaldosteronism can result from inherited changes that increase aldosterone production, including mutations affecting adrenal ion channels and steroidogenic enzymes. Understanding the contribution of 11-beta-monooxygenase activity helps distinguish these forms and guides genetic testing.
Primary hyperaldosteronism
Primary hyperaldosteronism is a common cause of secondary hypertension, and its evaluation includes assessing adrenal steroidogenic pathways in which CYP11B2 activity plays a central role. Research on the activity supports the development of diagnostic and therapeutic strategies for this condition.
From steroid 11-beta-monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP11B1 abolish 11-beta-hydroxylase activity? | CRISPR knockout in adrenal steroidogenic cells |
| Does a specific CYP11B1 variant alter cortisol precursor conversion? | Point-mutation knock-in followed by steroid profiling |
| Can ectopic CYP11B1 expression reproduce glucocorticoid-remediable aldosteronism? | Knock-in of regulatory element or overexpression construct |
| Does CYP11B2 overexpression increase aldosterone output? | Overexpression cell model with aldosterone assay |
| Can the activity be measured in non-adrenal tissue? | Recombinant expression in yeast mitochondria or bovine ovary model |
| Which ion channel mutations cooperate with steroidogenic changes? | Point-mutation knock-in of KCNJ5 or ATP1A1 with steroid readouts |
How to Study the steroid 11-beta-monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Recombinant enzyme assay | Conversion of steroid substrate to 11-beta-hydroxysteroid | Testing catalytic activity of CYP11B1/CYP11B2 variants |
| Mass spectrometry steroid profiling | Levels of cortisol, aldosterone, and intermediates | Diagnosis and model validation |
| RNA-seq | Expression of CYP11B1, CYP11B2, and related genes | Comparing adrenal versus ectopic expression |
| Western blot | Protein abundance of steroidogenic enzymes | Confirming knockout or overexpression |
| CRISPR knockout | Loss-of-function phenotype | Testing necessity of the activity |
| CRISPR knock-in | Effect of specific variants or regulatory elements | Modeling disease-associated alleles |
| Overexpression | Gain-of-function phenotype | Testing sufficiency of the activity |
| Bioinformatics screening | Candidate modifiers and pathway enrichment | Prioritizing genes for functional studies |
Biochemical activity assays
Direct measurement of 11-beta-monooxygenase activity can be performed using recombinant systems, such as yeast mitochondria expressing the enzyme, by monitoring conversion of 11-deoxycortisol to hydrocortisone. These assays provide a quantitative readout of catalytic function and are useful for testing variant effects.
Steroid profiling by mass spectrometry
Mass spectrometry-based steroid profiling measures the products of the activity, including 11-beta-hydroxysteroids and downstream hormones. This approach is used to characterize disease states and to validate cell models.
Transcript and protein expression analysis
RNA-seq and quantitative PCR can measure CYP11B1 and CYP11B2 expression, while western blotting or proteomics can confirm protein levels. These methods help distinguish changes in activity due to expression versus catalytic differences.
Genetic and functional genomics
Candidate variants can be introduced by CRISPR and tested for effects on activity. Library screening and bioinformatics can identify modifiers of steroidogenic pathways and prioritize variants for functional testing.
How CRISPR Can Be Used to Study GO:0004507 steroid 11-beta-monooxygenase activity
Knockout
CRISPR knockout of CYP11B1 or CYP11B2 can abolish the activity and reveal its requirement for cortisol or aldosterone production. Knockout cell models are useful for measuring precursor accumulation and for testing whether other enzymes can compensate.
Point Mutation
Point-mutation knock-in allows researchers to introduce disease-associated missense variants into the endogenous locus and measure their effect on catalytic activity. This approach is valuable for distinguishing benign polymorphisms from pathogenic variants.
Knock-in
Knock-in of regulatory elements or chimeric constructs can model conditions such as glucocorticoid-remediable aldosteronism, in which ectopic expression of the activity drives aldosterone excess. This helps link regulatory changes to disease phenotypes.
Overexpression
Overexpression of CYP11B1 or CYP11B2 can test whether increased activity is sufficient to raise glucocorticoid or mineralocorticoid output. Such models are useful for studying hyperaldosteronism and for screening modulators of the activity.
How EDITGENE Supports steroid 11-beta-monooxygenase activity Research
Researchers studying steroid 11-beta-monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in steroidogenesis or disease. EDITGENE provides CRISPR-based cell models and screening services that allow direct testing of knockout, point-mutation, knock-in, and overexpression hypotheses in relevant cellular backgrounds.
Contact EDITGENE today to design your custom CRISPR model for steroid 11-beta-monooxygenase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CYP11B1 Knockout HEK293 Cell Line | EDJ-KQ4410 | Human | 1584 | Details Get a Quote |
| CYP11B2 Knockout HEK293 Cell Line | EDJ-KQ50226 | Human | 1585 | Details Get a Quote |
| CYP11B1 Knockout HeLa Cell Line | EDJ-KQ53058 | Human | 1584 | Details Get a Quote |
| CYP11B2 Knockout HeLa Cell Line | EDJ-KQ53059 | Human | 1585 | Details Get a Quote |
| CYP11B1 Knockout A-549 Cell Line | EDJ-KQ61524 | Human | 1584 | Details Get a Quote |
| CYP11B2 Knockout A-549 Cell Line | EDJ-KQ61525 | Human | 1585 | Details Get a Quote |
| CYP11B1 Knockout HCT 116 Cell Line | EDJ-KQ70016 | Human | 1584 | Details Get a Quote |
| CYP11B2 Knockout HCT 116 Cell Line | EDJ-KQ70017 | Human | 1585 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About steroid 11-beta-monooxygenase activity
What is steroid 11-beta-monooxygenase activity?
It is the catalytic activity defined by GO:0004507, in which a steroid is hydroxylated at the 11-beta position using reduced adrenal ferredoxin and O2, producing an 11-beta-hydroxysteroid, oxidized adrenal ferredoxin, and water.
What genes are involved in steroid 11-beta-monooxygenase activity?
The main genes are CYP11B1 and CYP11B2, which encode the mitochondrial cytochrome P450 isozymes that carry out the reaction, along with electron transfer partners such as FDX1 and FDXR.
What is the difference between CYP11B1 and CYP11B2?
CYP11B1 primarily catalyzes 11-beta-hydroxylation for cortisol synthesis, while CYP11B2 can also perform 18-hydroxylation and 18-oxidation for aldosterone synthesis.
What diseases are linked to steroid 11-beta-monooxygenase activity?
Altered activity is linked to 11-beta-hydroxylase deficiency, glucocorticoid-remediable aldosteronism, familial hyperaldosteronism, and primary hyperaldosteronism.
How is steroid 11-beta-monooxygenase activity measured?
It can be measured by biochemical conversion assays in recombinant systems, such as yeast mitochondria converting 11-deoxycortisol to hydrocortisone, and by mass spectrometry-based steroid profiling.
Can steroid 11-beta-monooxygenase activity be studied outside the adrenal gland?
Yes, the activity has been detected in the bovine ovary, indicating that it can be studied in non-adrenal steroidogenic tissues.
What is glucocorticoid-remediable aldosteronism?
It is a form of hyperaldosteronism caused by ectopic expression of CYP11B1 in the aldosterone-producing zone, leading to aldosterone excess that can be suppressed by glucocorticoids.
Why is GO:0004507 important for drug discovery?
Because it controls cortisol and aldosterone production, modulating this activity could influence hypertension and adrenal disorders, making it a target for mechanistic and pharmacological studies.
What CRISPR models are used to study this activity?
Knockout, point-mutation, knock-in, and overexpression models are used to test loss- and gain-of-function effects on steroidogenesis and disease phenotypes.
Where can I get CRISPR cell models for CYP11B1 and CYP11B2?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services for steroidogenic genes including CYP11B1 and CYP11B2.
Conclusion
Steroid 11-beta-monooxygenase activity (GO:0004507) is a mitochondrial cytochrome P450 activity that determines the production of cortisol and aldosterone through 11-beta-hydroxylation of steroids. The isozymes CYP11B1 and CYP11B2 are the principal enzymes, and their dysfunction or dysregulation causes endocrine and hypertensive disorders. Studying this activity with biochemical assays, steroid profiling, and CRISPR models provides a direct route to understanding adrenal steroidogenesis and to testing candidate disease variants.
References
- 1. White PC et al.. 1994. Disorders of steroid 11 beta-hydroxylase isozymes.. Endocr Rev 15(4):421-38 PMID: 7988480
- 2. Halperin F et al.. 2011. Glucocorticoid-remediable aldosteronism.. Endocrinol Metab Clin North Am 40(2):333-41, viii PMID: 21565670
- 3. Dumas B et al.. 1996. 11 beta-hydroxylase activity in recombinant yeast mitochondria. In vivo conversion of 11-deoxycortisol to hydrocortisone.. Eur J Biochem 238(2):495-504 PMID: 8681964
- 4. Jamieson A et al.. 1996. Altered 11 beta-hydroxylase activity in glucocorticoid-suppressible hyperaldosteronism.. J Clin Endocrinol Metab 81(6):2298-302 PMID: 8964867
- 5. Kawamoto T et al.. 1992. Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans.. Proc Natl Acad Sci U S A 89(4):1458-62 PMID: 1741400
- 6. Amweg AN et al.. 2017. Detection and activity of 11 beta hydroxylase (CYP11B1) in the bovine ovary.. Reproduction 153(4):433-441 PMID: 28069904
- 7. Opocher G et al.. 1995. [Primary hyperaldosteronism].. Minerva Endocrinol 20(1):49-54 PMID: 7651282
- 8. Torpy DJ et al.. 2000. Familial hyperaldosteronism.. Braz J Med Biol Res 33(10):1149-55 PMID: 11004715
